Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

Although statin therapy is the cornerstone of dyslipidemia management, LDL-C lowering with statins reduces major coronary events by approximately one quarter, with 75% of events still occurring.

Multifactorial intensive therapies (including statins) are insufficient to prevent the development or progression of microvascular disease (retinopathy, nephropathy, neuropathy) in up to 50% of patients with the common form of diabetes (known as type 2 diabetes or T2D).